Somatropin (HGH) vs Vesugen
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone PeptidesAnti-Aging & Longevity
Somatropin (HGH)Anti-Aging & Longevity
Vesugen- Summary
- Somatropin is recombinant human growth hormone (rhGH), identical in structure to the 191-amino acid pituitary-derived growth hormone. It is FDA-approved for growth hormone deficiency, short stature, and wasting conditions. Off-label, it is widely explored for body composition, anti-aging, and performance enhancement, though significant risks accompany unsupervised use.
- Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
- Half-Life
- 2-3 hours (subcutaneous); 20-30 minutes (intravenous)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Subcutaneous, Intramuscular (less common)
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.15-0.3 mg/day (adults); titrated to IGF-1 levels
- 10 mg per day
- Frequency
- Once daily
- Daily for 10–30 days
- Key Benefits
- Increases lean muscle mass and reduces body fat (particularly visceral)
- Restores growth hormone deficiency (FDA-approved)
- Improves bone mineral density
- Enhances exercise capacity and recovery
- Supports skin thickness and collagen synthesis
- Improves lipid profile in GHD patients
- Explored for anti-aging and cellular regeneration
- Supports vascular endothelial cell function and integrity
- May reduce endothelial inflammation and dysfunction
- Anti-aging effects on blood vessel walls
- Potential benefits in early atherosclerosis and vascular aging
- Supports nitric oxide-mediated vascular tone
- Reduces endothelial apoptosis from oxidative stress
- Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
- Side Effects
- Fluid retention and edema (common, dose-dependent)
- Carpal tunnel syndrome
- Joint and muscle pain
- Insulin resistance and elevated blood glucose
- +3 more
- Generally well tolerated
- Mild injection site reactions
- No significant vascular adverse events reported at standard doses
- Stacks With
- —
- —